BackSingular Genomics Systems Overview

Singular Genomics Systems Total Current Liabilities

Singular Genomics Systems's total current liabilities is $18M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$17.61M
13.95% YoYΔ $2.16M vs prior year quarter

Peer average

Loading

Singular Genomics Systems Total Current Liabilities History

Loading

Singular Genomics Systems vs. peers: Total Current Liabilities Comparison

Loading

Singular Genomics Systems Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Singular Genomics Systems (OMIC) FAQ

Singular Genomics Systems (OMIC) currently reports a total current liabilities of $18M as of September 2024. That compares with $15M in the prior-year period — up 14.0% year over year. Use the charts on this page to explore Singular Genomics Systems's total current liabilities history and peer comparisons.

Singular Genomics Systems's total current liabilities increased from $15M to $18M — a 14.0% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Singular Genomics Systems reported $18M in total current liabilities as of September 2024. That compares with $15M in the prior-year period — up 14.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Singular Genomics Systems, and consider following OMIC for alerts when major investors trade the stock.

Singular Genomics Systems is classified in the Healthcare sector. On total current liabilities, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OMIC with unrelated industries.